- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.04. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.03. | Tyra Biosciences platziert Aktienpaket im Wert von 126 Mio. US-Dollar in Block-Trade | 3 | Investing.com Deutsch | ||
| 04.03. | Tyra Biosciences: Aktie auf Rekordhoch nach Kursrally von über 200 % | 5 | Investing.com Deutsch | ||
| 03.03. | Tyra Biosciences: H.C. Wainwright bekräftigt "Buy"-Rating und Kursziel von 45 Dollar | 1 | Investing.com Deutsch | ||
| 02.03. | Tyra Biosciences GAAP EPS of -$0.57 misses by $0.04 | 1 | Seeking Alpha | ||
| TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 02.03. | Tyra Biosciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 02.03. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.03. | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | 293 | PR Newswire | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| 10.02. | William Blair startet Coverage für Tyra Biosciences mit "Outperform"-Rating | 2 | Investing.com Deutsch | ||
| 10.02. | William Blair initiates coverage on Tyra Biosciences stock with Outperform rating | 1 | Investing.com | ||
| 28.01. | Tyra Biosciences stock price target raised to $55 from $35 at Raymond James | 4 | Investing.com | ||
| 23.01. | Tyra Biosciences: Piper Sandler erhöht Kursziel wegen Wachstumsaussichten auf 42 US-Dollar | 1 | Investing.com Deutsch | ||
| 23.01. | Piper Sandler raises Tyra Biosciences stock price target to $42 on growth outlook | 2 | Investing.com | ||
| 16.12.25 | Wedbush raises Tyra Biosciences stock price target to $37 on pipeline potential | 1 | Investing.com | ||
| 04.12.25 | Goldman Sachs initiates coverage of Tyra Biosciences stock with Early-Stage Biotech rating | 1 | Investing.com | ||
| 01.12.25 | Tyra Biosciences appoints two key executives to leadership team | 1 | Investing.com | ||
| 01.12.25 | Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer | 287 | PR Newswire | CARLSBAD, Calif., Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation... ► Artikel lesen | |
| 01.12.25 | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.25 | Tyra Biosciences GAAP EPS of -$0.50 beats by $0.05 | 1 | Seeking Alpha | ||
| 05.11.25 | Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights | 253 | PR Newswire | - Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 -
- Expanded development of dabogratinib... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 16,310 | 0,00 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| ALLOGENE THERAPEUTICS | 3,050 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation ... | 41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,140 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 316,75 | 0,00 % | Praxis Precision Medicines: Raymond James sieht Kurspotenzial von über 150 % | ||
| NURIX THERAPEUTICS | 15,910 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| MAZE THERAPEUTICS | 27,420 | 0,00 % | Zifo Technologies: Zifo and Maze Therapeutics Partner to Power Precision Medicine | SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- Zifo, the leading global enabler of AI and data-driven enterprise informatics for science driven organizations and Maze Therapeutics Inc have... ► Artikel lesen | |
| CG ONCOLOGY | 67,67 | -0,04 % | CG Oncology, Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 21,540 | 0,00 % | Leerink raises Tango Therapeutics stock price target on PDAC data | ||
| ADMA BIOLOGICS | 10,370 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,500 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| QIAGEN | 36,125 | +2,19 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| EVOTEC | 5,135 | +9,26 % | Evotec nominiert ehemaligen Bayer-Manager als Aufsichtsratschef | Evotec SE hat Dieter Weinand als Kandidaten für den Vorsitz des Aufsichtsrats nominiert. Die Hauptversammlung am 11. Juni 2026 soll über seine Wahl abstimmen. Weinand war zuvor unter anderem Vorstandsmitglied... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 5,200 | 0,00 % | Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update | In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 88,51 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen | |
| ARCELLX | 114,85 | 0,00 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen |
TYRA BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 35,610 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TYRA BIOSCIENCES INC finden Sie auf Wallstreet Online.